Creative Medical Technology Stock Price, News & Analysis (NASDAQ:CELZ) $4.57 +0.12 (+2.70%) (As of 12/1/2023 ET) Add Compare Share Share Today's Range$4.37▼$4.5750-Day Range$4.22▼$5.4552-Week Range$3.46▼$14.20Volume1,603 shsAverage Volume5,438 shsMarket Capitalization$6.31 millionP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock AnalysisChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSocial Media Creative Medical Technology MarketRank™ Stock AnalysisAnalyst RatingN/AUpside/DownsideN/AShort InterestHealthy2.67% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment1.29Based on 2 Articles This WeekInsider TradingN/AProj. Earnings GrowthDecreasingFrom ($3.68) to ($4.62) Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.1.53 out of 5 stars N/A Analyst's Opinion Consensus RatingThere is not enough analysis data for Creative Medical Technology. Previous Next 5.0 Short Interest Percentage of Shares Shorted2.67% of the float of Creative Medical Technology has been sold short.Short Interest Ratio / Days to CoverCreative Medical Technology has a short interest ratio ("days to cover") of 1.3, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Creative Medical Technology has recently decreased by 5.74%, indicating that investor sentiment is improving significantly. Previous Next 0.0 Dividend Strength Dividend YieldCreative Medical Technology does not currently pay a dividend.Dividend GrowthCreative Medical Technology does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for CELZ. Previous Next 2.9 News and Social Media Coverage News SentimentCreative Medical Technology has a news sentiment score of 1.29. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.76 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 2 news articles for Creative Medical Technology this week, compared to 0 articles on an average week. Previous Next 0.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Creative Medical Technology insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 3.30% of the stock of Creative Medical Technology is held by insiders.Percentage Held by InstitutionsOnly 1.41% of the stock of Creative Medical Technology is held by institutions. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Creative Medical Technology are expected to decrease in the coming year, from ($3.68) to ($4.62) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Creative Medical Technology is -0.59, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Creative Medical Technology is -0.59, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioCreative Medical Technology has a P/B Ratio of 0.52. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About Creative Medical Technology Stock (NASDAQ:CELZ)Creative Medical Technology Holdings, Inc., a biotechnology company, focuses on immunology, urology, orthopedics, and neurology using adult stem cell treatments. The company offers CaverStem to treat erectile dysfunction; FemCelz for the treatment of loss of genital sensitivity and dryness; StemSpine to treat chronic lower back pain; ImmCelz for the treatment of stroke patients; and OvaStem for treatment of female infertility. Creative Medical Technology Holdings, Inc. is based in Phoenix, Arizona.Read More CELZ Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart CELZ Stock News HeadlinesNovember 26, 2023 | americanbankingnews.comHead-To-Head Contrast: Creative Medical Technology (CELZ) & The CompetitionOctober 11, 2023 | msn.comCreative Medical to initiate trial of lower back pain treatmentDecember 3, 2023 | Wealthpress (Ad)Trading Experts Call It “The Perfect Tesla Trade”Thanks to a new discovery linked to shares of Tesla, regular folks can now target gains of 100% or more in six days or less. New research shows it’s happened 23 different times this year. The next trade is scheduled for this Thursday.October 10, 2023 | markets.businessinsider.comCreative Medical Gets IRB Approval For StemSpine Trial Using AlloStem Cell TherapyOctober 10, 2023 | finance.yahoo.comCreative Medical Technology Holdings Announces IRB Approval for FDA Cleared Phase 1/2 Clinical Trial of StemSpine® using AlloStem™ ("CELZ-201-DDT") Novel Cell Therapy to Treat Chronic Lower Back PainSeptember 22, 2023 | finance.yahoo.comWhat Makes Creative Medical Technology Holdings, Inc. (CELZ) a New Buy StockSeptember 19, 2023 | finance.yahoo.comCreative Medical Technology Holdings Receives FDA Clearance to Initiate a Phase 1/2 Clinical Trial of StemSpine® using AlloStem™ (CELZ-201-DDT) for the Treatment of Chronic Lower Back PainAugust 24, 2023 | finance.yahoo.comWhat Is Allogeneic Cell Therapy, And What’s Driving This Market’s 25%+ Annual Global Growth?December 3, 2023 | DTI Trader (Ad)All the trading advice you’ve ever received boils down to thisAll the trading advice you’ve ever received boils down to one goal and one goal only: finding a reliable edge in the markets. If you can do that, grab hold of it and never let go. Because once you have that edge, and you can count on it, you never need to do anything else.August 23, 2023 | benzinga.comWhat Is Allogeneic Cell Therapy, And What's Driving This Market's 25%+ Annual Global Growth?June 28, 2023 | msn.comCreative Medical Technology regains Nasdaq listing complianceJune 12, 2023 | finance.yahoo.comCreative Medical Technology Holdings Provides Corporate UpdateJune 12, 2023 | finance.yahoo.comCreative Medical Technology Announces $2 Million Share Repurchase ProgramJune 9, 2023 | msn.comCreative Medical Technology Holdings announces reverse stock split to regain complianceMay 31, 2023 | finance.yahoo.comCreative Medical Technology Holdings Announces Successful Completion of the First Phase of its Program with Greenstone Biosciences, Inc. to Develop Next Generation iPSC Pipeline for ImmCelz® Immunotherapy PlatformMay 18, 2023 | msn.comCreative Medical Releases Data From StemSpine Procedure For Chronic Lower Back PainMay 18, 2023 | finance.yahoo.comCreative Medical Technology Holdings Announces Positive Top-Line Study Results for Chronic Lower Back Pain Utilizing its StemSpine® Procedure Using AlloStem™ Allogenic Cell LineMay 14, 2023 | finance.yahoo.comCreative Medical Technology Holdings First Quarter 2023 Earnings: US$0.075 loss per share (vs US$0.18 loss in 1Q 2022)April 13, 2023 | msn.comCreative Medical (CELZ) Up 86% on Upbeat Diabetes Study DataApril 12, 2023 | msn.comCreative Medical Technology Soars after Positive Drug DataApril 12, 2023 | benzinga.comThinking about buying stock in Newmark Group, Exscientia, Pardes Biosciences, Creative Medical Technology, or Somalogic?April 12, 2023 | msn.comWhy Is Creative Medical Technology Stock Skyrocketing Today?April 4, 2023 | finance.yahoo.comCreative Medical Technology Holdings Announces Filing of 2022 Form 10-K and Provides Business UpdateMarch 23, 2023 | msn.comCreative Medical stock rises on seeking FDA orphan drug status for Brittle diabetes therapyMarch 23, 2023 | finance.yahoo.comCreative Medical Technology Files Orphan Drug Designation Application with the U.S. FDA Using the ImmCelz® Platform for the Treatment of Brittle Type 1 DiabetesMarch 21, 2023 | finance.yahoo.comCreative Medical Technology Holdings Announces Key Milestones Regarding ImmCelz® Platform DevelopmentMarch 7, 2023 | finance.yahoo.comCreative Medical Technology Holdings Engages Highly Respected International CRO for Phase 1 / 2 Clinical Trial to Treat Type 1 Diabetes Using CELZ-201See More Headlines Receive CELZ Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Creative Medical Technology and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Today12/03/2023Fiscal Year End12/31/2023Next Earnings (Estimated)3/29/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Biological products, except diagnostic Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:CELZ CUSIPN/A CIK1187953 Webwww.creativemedicaltechnology.com Phone(833) 336-7636FaxN/AEmployees4Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)($7.80) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-10,140,000.00 Net MarginsN/A Pretax Margin-39,296.00% Return on Equity-69.54% Return on Assets-64.36% Debt Debt-to-Equity RatioN/A Current Ratio28.61 Quick Ratio28.59 Sales & Book Value Annual Sales$90,000.00 Price / Sales70.07 Cash FlowN/A Price / Cash FlowN/A Book Value$8.75 per share Price / Book0.52Miscellaneous Outstanding Shares1,380,000Free Float1,336,000Market Cap$6.31 million OptionableNot Optionable Beta2.25 5G Stocks: The Path Forward is ProfitableClick the link below and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise. Get This Free Report Key ExecutivesMr. Timothy Warbington (Age 61)Co-Founder, Chairman, President & CEO Comp: $429kMr. Donald Dickerson (Age 58)Senior VP, CFO & Director Comp: $390kKey CompetitorsBrickell BiotechNASDAQ:BBIFinch Therapeutics GroupNASDAQ:FNCHTRACON PharmaceuticalsNASDAQ:TCONAvalon GloboCareNASDAQ:ALBTTitan PharmaceuticalsNASDAQ:TTNPView All CompetitorsInsidersTimothy WarbingtonBought 800 shares on 6/27/2023Total: $3,552.00 ($4.44/share)View All Insider Transactions CELZ Stock Analysis - Frequently Asked Questions How have CELZ shares performed in 2023? Creative Medical Technology's stock was trading at $3.8110 on January 1st, 2023. Since then, CELZ shares have increased by 19.9% and is now trading at $4.57. View the best growth stocks for 2023 here. Are investors shorting Creative Medical Technology? Creative Medical Technology saw a decline in short interest in the month of November. As of November 15th, there was short interest totaling 36,100 shares, a decline of 5.7% from the October 31st total of 38,300 shares. Based on an average daily trading volume, of 27,700 shares, the days-to-cover ratio is currently 1.3 days. Approximately 2.7% of the shares of the company are short sold. View Creative Medical Technology's Short Interest. When is Creative Medical Technology's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Friday, March 29th 2024. View our CELZ earnings forecast. When did Creative Medical Technology's stock split? Shares of Creative Medical Technology reverse split on the morning of Sunday, June 11th 2023. The 1-10 reverse split was announced on Sunday, June 11th 2023. The number of shares owned by shareholders was adjusted after the closing bell on Sunday, June 11th 2023. An investor that had 100 shares of stock prior to the reverse split would have 10 shares after the split. How do I buy shares of Creative Medical Technology? Shares of CELZ stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. This page (NASDAQ:CELZ) was last updated on 12/3/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Creative Medical Technology Holdings, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.